|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
In this trial, monoclonal anti-Disialoganglioside GD2 (GD2) antibody ch14.18/CHO will be assessed for the treatment of patients with relapsed or refractory neuroblastoma. The antibody is used as a single agent applied in a new treatment schedule associated with less side effects.
100 Clinical Results associated with Children'S Cancer Research Institute
0 Patents (Medical) associated with Children'S Cancer Research Institute
100 Deals associated with Children'S Cancer Research Institute
100 Translational Medicine associated with Children'S Cancer Research Institute